With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
In a surprising move, Novartis snapped up preclinical-stage Kate Therapeutics for over a billion dollars—signaling renewed confidence in …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
Exploring recent advancements in CRISPR therapies, personalized gene editing, and artificial intelligence transforming drug development and clinical trials.
In 2024, the European Medicines Agency (EMA) recommended a record 114 new medicines for approval, showcasing major advances …
Cutting-edge biomarker technologies are enabling faster, more accurate cancer diagnosis and tailored therapies, revolutionizing precision oncology.
With a blockbuster IPO on the horizon, Australian biotech innovation is drawing global eyes and fresh capital to …
A new multinational clinical trial marks a significant step in developing transformative gene therapies for rare inherited disorders.
New partnerships and funding rounds are powering the rapid growth of RNA therapeutics.
Moderna pushes the boundaries of mRNA therapy into rare genetic diseases, aiming for transformative treatments.
Already a subscriber? Log in